{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:00:23Z","timestamp":1784869223745,"version":"3.55.0"},"reference-count":24,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Invasive cutaneous melanoma is responsible for about 5% of skin tumors yet is liable for nearly 70% of skin cancer-related deaths. Despite notable advancements over the past decade, including immunotherapies and targeted treatments, more than half of invasive melanoma patients ultimately succumb to the disease due to therapeutic resistance. To overcome this obstacle, strategies such as combining immunotherapies with targeted drugs or adding epigenetic therapies have been investigated. Tumor-infiltrating lymphocytes (TILs) therapy has emerged as a promising option for patients whose disease continues to progress despite standard treatments. This article aims to introduce TIL therapy and review recent outcomes in melanoma prognosis in its application for melanoma management.<\/jats:p>","DOI":"10.3390\/ijms252312596","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T03:59:01Z","timestamp":1732507141000},"page":"12596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in Tumor-Infiltrating Lymphocyte (TIL) as a Prognostic Factor and for Treating Invasive Cutaneous Melanoma"],"prefix":"10.3390","volume":"25","author":[{"given":"Gabriel Alves Freiria","family":"de Oliveira","sequence":"first","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo (EPM\/UNIFESP), Rua Botucatu, 740, S\u00e3o Paulo 04023-062, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-041X","authenticated-orcid":false,"given":"Daniel Arcuschin","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo (EPM\/UNIFESP), Rua Botucatu, 740, S\u00e3o Paulo 04023-062, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Yoshimi Sakamoto Maeda","family":"Nisimoto","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo (EPM\/UNIFESP), Rua Botucatu, 740, S\u00e3o Paulo 04023-062, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rubinho","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universidade Santo Amaro, Rua Isabel Schmidt, 349, Santo Amaro, S\u00e3o Paulo 04743-030, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heitor Carvalho","family":"Gomes","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo (EPM\/UNIFESP), Rua Botucatu, 740, S\u00e3o Paulo 04023-062, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3890-0827","authenticated-orcid":false,"given":"Luciana Cavalheiro","family":"Marti","sequence":"additional","affiliation":[{"name":"Department of Experimental Research, Hospital Israelita Albert Einstein, Rua Comendador Elias Jafet, 755, Morumbi, S\u00e3o Paulo 05653-000, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-973X","authenticated-orcid":false,"given":"Renato Santos","family":"de Oliveira Filho","sequence":"additional","affiliation":[{"name":"Melanoma and Skin Tumors Sector, Plastic Surgery Discipline, Escola Paulista de Medicina\/Universidade Federal de S\u00e3o Paulo (EPM\/UNIFESP), Rua Botucatu, 740, S\u00e3o Paulo 04023-062, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"(2024, February 22). AIM at Melanoma Foundation. Available online: https:\/\/www.aimatmelanoma.org\/facts-statistics\/."},{"key":"ref_4","unstructured":"(2024, February 10). INCA (Instituto Nacional de C\u00e2ncer\u2014Brazil), Available online: https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/pele-melanoma."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11912-022-01243-x","article-title":"Triplet Therapy in Melanoma\u2014Combined BRAF\/MEK Inhibitors and Anti-PD-(L)1 Antibodies","volume":"24","author":"Patel","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"de Oliveira Filho, R.S., de Oliveira, D.A., Nishimoto, M.M., and Marti, L.C. (2023). A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors. Cancers, 15.","DOI":"10.3390\/cancers15245751"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Knight, A., Karapetyan, L., and Kirkwood, J.M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15.","DOI":"10.3390\/cancers15041106"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","article-title":"Tumor-infiltrating lymphocytes: A new hope","volume":"42","author":"Sarnaik","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-53156-4_2","article-title":"Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy","volume":"995","author":"Dhupkar","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: Impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e000848","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"Heemskerk","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_12","first-page":"2700","article-title":"The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma","volume":"25","author":"Buiga","year":"2020","journal-title":"J. BUON"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"770775","DOI":"10.1007\/s13193-021-01427-0","article-title":"Tumor-Infiltrating Lymphocytes in Patients with Melanoma: Which Is Its Prognostic Value?","volume":"12","author":"Angeramo","year":"2021","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Klein, S., Mauch, C., Brinker, K., Noh, K.W., Knez, S., B\u00fcttner, R., Quaas, A., and Helbig, D. (2021). Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E\/K mutated malignant melanomas. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-81330-4"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00432-021-03565-y","article-title":"Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma","volume":"147","author":"Tas","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3892\/mco.2021.2417","article-title":"Addressing the importance of melanoma tumor-infiltrating lymphocytes in disease progression and clinicopathological characteristics","volume":"15","author":"Zablocka","year":"2021","journal-title":"Mol. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1245\/s10434-021-11251-z","article-title":"Is There a Relationship Between TILs and Regression in Melanoma?","volume":"29","author":"Morrison","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Aung, T.N., Shafi, S., Wilmott, J.S., Nourmohammadi, S., Vathiotis, I., Gavrielatou, N., Fernandez, A., Yaghoobi, V., Sinnberg, T., and Amaral, T. (2022). Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine, 82.","DOI":"10.1016\/j.ebiom.2022.104143"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1245\/s10434-022-11478-4","article-title":"Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort","volume":"9","author":"Straker","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e150535","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14712598.2023.2193290","article-title":"Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma","volume":"23","author":"Julve","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","article-title":"Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future","volume":"29","author":"Corrie","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"eadg7995","DOI":"10.1126\/sciimmunol.adg7995","article-title":"Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma","volume":"9","author":"Barras","year":"2024","journal-title":"Sci. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:38:06Z","timestamp":1760114286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/23\/12596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":24,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijms252312596"],"URL":"https:\/\/doi.org\/10.3390\/ijms252312596","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]}}}